All lobbying filings
FOUNDATION MEDICINE, INC.
FOUNDATION MEDICINE, INC. filed a Q2 report for FOUNDATION MEDICINE, INC. on July 18, 2025.
Lobbying for FOUNDATION MEDICINE, INC.
Filing · LD-2 quarterly report
Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 18, 2025
Expenses
$80,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Massachusetts
Government bodies contacted
3
Lobbying activity
1
- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory